Business Wire

Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury

Share

Vectura Group plc (LSE:VEC) ("Vectura" or "the Group") confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s (GSK) Ellipta products. The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of these products. Vectura expects to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021. The jury also found that GSK’s infringement was willful. The willfulness finding gives Vectura the right to seek enhanced damages. GSK has the option to appeal the decision.

James Ward-Lilley, Chief Executive Officer of Vectura, commented:

“Although we regret the need to take a longstanding partner to court, we are pleased with the jury’s verdict which confirms the validity of our intellectual property and the decision to progress this action with GSK. We will provide updates on this matter in due course.”

Background to litigation:

In July 2016, Vectura filed a patent infringement lawsuit against GSK in the United States District Court for the District of Delaware claiming that sales of certain GSK Ellipta products infringed Vectura patents.

Vectura and GSK had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family. These licensed patents expired in July 2016. At this time GSK had the option to license additional patent families under the original agreement but declined to do so, resulting in the filing of the lawsuit by Vectura.

From the outset Vectura has been open to finding a mutually acceptable solution to avoid prolonging the dispute. Those efforts were not fruitful and led to the litigation progressing to a jury trial in April 2019.

Expected news flow for 2019

In the meantime, we continue to focus on executing our strategy and to build on our recently reported strong financial and operational progress. Further expected news flow for 2019 includes:

  • VR315 (US) repeat clinical study read-out and resubmission
  • VR647 (US) partnering post FDA end of Phase II meeting
  • Updated disclosure on new nebulised niche portfolio assets, including potential orphan drug designation
  • QVM149 Phase III study completion and submission

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at www.vectura.com

Contact information

Vectura Group plc
David Ginivan – VP Corporate Communications
+44 (0)7471 352 720
Elizabeth Knowles – VP Investor Relations
+44 (0)7767 160 565

Consilium Strategic Communications
+44 (0)7739 788 014
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

STALICLA Announces Completion of pre-IND Meeting With FDA on STP1 for Subgroup of Patients With Autism Spectrum Disorder (ASD)23.8.2019 00:00:00 CESTPress release

STALICLA, a Swiss Biotech company, today announced the completion of its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) on the preparation for entry of STP1 into clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005559/en/ STALICLA at the Food and Drug Administration (FDA) to discuss its investigational precision medicine for Autism Spectrum Disorder (Photo: STALICLA) “We are appreciative of FDA´s technical guidance and strong interest in personalized medicine approaches for patients with Autism Spectrum Disorder. STALICLA is committed to rapidly move forward with the submission of its STP1 IND. STP1 holds the potential to become the first precision medicine for a subgroup of patients with ASD, and herald a new age for this field.” - Lynn Durham, CEO and Founder of STALICLA. ASD is a common neurodevelopmental disorder, with high level of heterogeneity, that aff

San Fang Chemical Switches to Rimini Street Support for its Oracle EBS and Oracle Database Software22.8.2019 22:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that San Fang Chemical Co., Ltd., a global manufacturer and distributor of artificial leather products headquartered in Taiwan, has switched to Rimini Street support for its Oracle E-Business Suite application and Oracle Database software. In addition to immediately saving 50% of its annual maintenance costs that they were previously paying the vendor, the company can now maintain its core, robust Oracle system for a minimum of 15 years from the time that they switched to Rimini Street support with no forced upgrades. San Fang Chemical has also been able to liberate its IT resources and divert its substantial cost savings to invest in more forward-looking innovation projects to help pave the way for future growth and competitive advantage. This press release features mu

Gravity Unveils its Future Plans During Gamescom 201922.8.2019 15:46:00 CESTPress release

Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany from August 20th to 24th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005507/en/ Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany. At the fair, Gravity announced that it plans to launch ‘Ragnarok M: Eternal Love’ in the European region on September 4th 2019. ‘Ragnarok M: Eternal Love’ will be launched in Russia and Turkey, as well as Europe and it will be serviced in seven languages including English, Portuguese, Spanish, Russian, German, French, and Turkish. (Photo: Business Wire) On August 20th, Gravity held a presentati

RoboSense and Aidrivers Announce a Partnership to Deliver Superior Autonomous Solutions for Industrial Transportation22.8.2019 14:55:00 CESTPress release

RoboSense, the leading supplier of LiDAR perception system solutions, and Aidrivers, the UK's leading provider of autonomous mobility solutions for industrial applications announced today a partnership in system integration. Aidrivers will integrate RoboSense Smart LiDAR Sensor System into their own Autonomous Driving Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005468/en/ RoboSense and Aidrivers announce a partnership to deliver superior autonomous solutions for industrial transportation Aidrivers is delivering a fully autonomous natural navigation system that meets industrial safety standards to seaports, particularly for horizontal transportation, aimed for improving operation efficiency and leading the way in industrial autonomous mobility automation. Their solution can work under all harsh weather conditions by achieving true 3D mapping and localization for precision positioning and situation cognisance

Alight to Acquire NGA Human Resources, One of the Largest Multi-Country Payroll and HR Solutions Providers in the World22.8.2019 14:00:00 CESTPress release

Alight Solutions, a leader in technology-enabled health, wealth and human capital management (HCM) and financial management solutions, today announced it has signed a definitive agreement to acquire NGA Human Resources, a leading provider of digital HR and multi-country payroll services. The proposed transaction is subject to customary closing conditions. With a nearly 50-year history, NGA HR brings innovation, high-quality service, HR and payroll expertise to its more than 250 clients, representing three million employees. As one of the largest multinational payroll providers, NGA HR is enabled to deliver HR & payroll services across more than 188 countries. Underpinning NGA HR’s HR and payroll expertise is its industry leading technology platforms including hrX, which provides companies with a centralized point to access their payroll and HR solutions including analytics; and its euHReka multi-tenant cloud payroll platform, which is localized to support payroll in 51 different countr

Andersen Global Premieres in Colombia22.8.2019 13:30:00 CESTPress release

Andersen Global is proud to announce a collaboration agreement with a law firm in Colombia. Bogotá D.C.- based Jiménez, Higuita, Rodríguez & Asociados (JHR Corp.) is the first firm with which Andersen Global has developed a presence in the country. Colombia is the tenth country in Latin America in which Andersen Global has a presence with nearly 900 total professionals in the region. JHR, founded in 2017, employs approximately 50 legal and tax professionals, each with deep legal experience within accounting. JHR provides services to national and foreign companies, both private and public, and specializes in tax, customs, and exchange law. “We are a young firm, but we have a desire to be the very best in Colombia,” said Julián Jiménez Mejía, JHR Office Managing Director. “That drive has enabled us to grow so quickly and double our size in just two years. Our ambitions for our firm continue to increase, and we look forward to broadening our service capabilities and ability to provide sea